5 Minutes with Dr Louise Jackett

5 Minutes with Dr Louise Jackett

27 April 2016

To educate the next generation of melanoma researchers and doctors, MIA offers a number of unique clinical and research-based Fellowships each year. They are made possible thanks to the generosity of our donors.

Dr Louise Jackett is our 2016 Jani Haenke Melanoma Pathology Fellow. 

Why did you apply for our Fellowship program?

I was drawn to the Melanoma Pathology Fellowship at MIA for the chance to work with a team at the forefront of melanoma research. Also, the diagnosis of melanoma and other melanocytic lesions under the microscope can be very difficult and this role allows me to learn from the best.

Tell us about your role with MIA?

I combine research activities and reporting of melanoma cases. Many of these cases are for patients treated at MIA but some are difficult cases that have come from pathologists nation-wide or internationally for expert opinion and I find these challenging and very interesting.

What drives you to come to work each day?

I find huge value in providing important information about patients’ health conditions. I also stay mindful of the generous donors who make my position possible.

Where did you work before coming to MIA?

I undertook my primary medical degree (MBBS, BMedSci) at the University of Tasmania and moved to Melbourne when I was a resident medical officer. There I pursued my anatomical pathology training over 5 years and recently gained fellowship with the Royal College of Pathologists of Australasia.

What are you hoping to achieve through your Fellowship at MIA?

I am hoping to increase my expertise in the tricky aspects of melanoma diagnosis, such as atypical melanocytic lesions and their distinction from melanoma. During the year I hope to publish on several projects that I am personally driving, as well as collaborating with many other MIA researchers by providing a pathological viewpoint and expertise. 

What do you like to do in your spare time?

I like to counteract my sedentary microscope work by being very active! I love running, cycling and yoga.

Melanoma Information Forum
06 Nov 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
23 Aug 2019

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Team Melanoma smashes City2Surf
16 Aug 2019

Team Melanoma smashes City2Surf

We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
08 Aug 2019

Ready to run over melanoma at City2Surf 2019

Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
01 Aug 2019

Community Fundraising July Wrap-Up

MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in the month of July that are helping us move closer to our goal of zero deaths from melanoma.

Breast cancer drug may hold key to tackling most deadly type of melanoma
23 Jul 2019

Breast cancer drug may hold key to tackling most deadly type of melanoma

An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.

MIA takes centre stage at leading cancer conference
05 Jun 2019

MIA takes centre stage at leading cancer conference

Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma is treated .

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.

Emma Betts' legacy will live on
17 May 2019

Emma Betts' legacy will live on

“I’m the age Emma was when she passed away. It almost feels unfair, that she has to not be here for me to be able to do this. But I will use this opportunity to push as hard as I can to reach our collective goal of zero deaths from melanoma.”

Support PBS listing for three adjuvant treatments of resected Stage III melanoma
13 May 2019

Support PBS listing for three adjuvant treatments of resected Stage III melanoma

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

Support PBS listing for pembrolizumab
06 May 2019

Support PBS listing for pembrolizumab

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.